ADAP vs. TNYA, SRNE, CCCC, ABOS, FUSN, IVVD, ARYD, FENC, GNFT, and OCGN
Should you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Tenaya Therapeutics (TNYA), Sorrento Therapeutics (SRNE), C4 Therapeutics (CCCC), Acumen Pharmaceuticals (ABOS), Fusion Pharmaceuticals (FUSN), Invivyd (IVVD), ARYA Sciences Acquisition Corp IV (ARYD), Fennec Pharmaceuticals (FENC), Genfit (GNFT), and Ocugen (OCGN). These companies are all part of the "biological products, except diagnostic" industry.
Adaptimmune Therapeutics vs.
Tenaya Therapeutics (NASDAQ:TNYA) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, community ranking, institutional ownership and risk.
In the previous week, Adaptimmune Therapeutics had 3 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 5 mentions for Adaptimmune Therapeutics and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.93 beat Adaptimmune Therapeutics' score of 0.58 indicating that Tenaya Therapeutics is being referred to more favorably in the media.
Tenaya Therapeutics has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Adaptimmune Therapeutics has a beta of 2.22, indicating that its stock price is 122% more volatile than the S&P 500.
Tenaya Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 650.99%. Adaptimmune Therapeutics has a consensus target price of $6.12, indicating a potential upside of 456.36%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Adaptimmune Therapeutics.
Tenaya Therapeutics has higher earnings, but lower revenue than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics received 293 more outperform votes than Tenaya Therapeutics when rated by MarketBeat users. Likewise, 63.67% of users gave Adaptimmune Therapeutics an outperform vote while only 63.16% of users gave Tenaya Therapeutics an outperform vote.
Tenaya Therapeutics has a net margin of 0.00% compared to Adaptimmune Therapeutics' net margin of -609.46%. Tenaya Therapeutics' return on equity of -54.20% beat Adaptimmune Therapeutics' return on equity.
Summary
Tenaya Therapeutics beats Adaptimmune Therapeutics on 9 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ADAP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adaptimmune Therapeutics Competitors List
